Retatrutide, also known as LY3437943, is a peptide designed to activate three metabolic hormone receptors: GIP, GLP-1 and glucagon. It is being studied for its effects on glucose regulation, appetite, energy balance and body weight.
Studied Uses
Retatrutide has been investigated in clinical research involving:
- Obesity and overweight
- Body-weight and body-composition changes
- Type 2 diabetes and glycaemic control
- Appetite and food-intake regulation
- Metabolic dysfunction-associated liver fat
- Cardiovascular and kidney outcomes
- Obesity-related conditions such as knee osteoarthritis
Phase 2 research evaluated retatrutide in adults with obesity or overweight, while ongoing and recently reported Phase 3 trials have examined obesity, type 2 diabetes and associated metabolic conditions.
Retatrutide remains investigational and is not currently an FDA-approved medication.
How It Works
Retatrutide acts as a single-molecule agonist at the GIP, GLP-1 and glucagon receptors.
GIP and GLP-1 receptor activation influences glucose-dependent insulin signalling, appetite and food intake. Glucagon-receptor activation affects liver metabolism and energy expenditure. Researchers are studying whether activating all three pathways together can produce complementary effects on glucose control, appetite regulation, energy balance and body weight.
Product Details
Product: Retatrutide
Strength: 20 mg
Form: Lyophilized powder
Presentation: Single vial
Reviews
There are no reviews yet.